Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
Lilly buys inflammation biotech Ventyx for $1.2B
Ventyx achieved its goal of securing Big Pharma commitment to its pipeline, with Lilly swooping in to buy the inflammation biotech for $1.2 billion.
James Waldron
Jan 8, 2026 7:01am
Hope springs toward Parkinson's phase 3 despite divergent data
Dec 23, 2025 9:00am
Aspen adds $115M series C to grow cell therapy ambitions
Nov 20, 2025 7:02am
Merck KGaA becomes latest partner for Flagship’s Valo Health
Nov 20, 2025 6:30am
Inbrain Neuroelectronics in pact with Microsoft to leverage AI
Nov 11, 2025 8:50am
Takeda drops AZ-partnered neurological program after ph. 2 fail
Oct 30, 2025 9:25am
